NDA Partners LLC: A Development Partner to Biopharmaceutical Investors and Companies

Anders Grahnén, PhD (Pharm)

Practice Area Focus

  • Development Stratgey
  • Clinical Trial Methodology
  • Regulatory Strategy
  • EU Registration Requirements


Dr. Grahnén is an NDA Partners Premier Expert consultant specializing in early clinical development and European pharmaceutical regulatory affairs. He was previously Chief Scientific Officer and QP at Quintiles AB (Uppsala, Sweden) and Adjunct Professor of Clinical Trial Methodology, Faculty of Pharmacy at Uppsala University. Prior to joining Quintiles, Dr Grahnén held increasing levels of responsibility from 1976-1988 in the Department of Drugs, National Board of Health and Welfare (Swedish equivalent of FDA). He received his PhD in Pharmacokinetics and Biopharmaceutics from Uppsala University and is a licensed Pharmacist.